HPV prevalence and HPV genotype distribution by sex
| Total | Gender | HIV serostatus | HPV genotype coverage | |||||
| Male | Female | Negative | Positive | Gardasil | Cervarix | Gardasil 9 | ||
| Total subjects, n | 412 | 176 | 236 | 391 | 21 | |||
| Number of HPV infections, n | 351 | 25 | 326 | 305 | 46 | |||
| Subjects with at least 1 HPV infection*, n (%) | 168 (40.8) | 18 (10.2) | 150 (63.6) | 154 (39.4) | 14 (66.7) | |||
| Subjects with hr-HPV infections†, n (%) | 115 (27.9) | 10 (5.7) | 105 (44.5) | 104 (26.6) | 11 (52.4) | |||
| 16 | 24 (5.8) | 1 (0.6) | 23 (9.7) | 22 (5.6) | 2 (9.5) | ++++ | ++++ | ++++ |
| 18 | 11 (2.7) | 0 (0.0) | 11 (4.7) | 10 (2.6) | 1 (4.8) | ++++ | ++++ | ++++ |
| 31 | 6 (1.5) | 1 (0.6) | 5 (2.1) | 5 (1.3) | 1 (4.8) | ++++ρ | ++++§ | ++++ |
| 33 | 4 (1.0) | 0 (0.0) | 4 (1.7) | 2 (0.5) | 2 (9.5) | ++++ρ | ++++ρ | ++++ |
| 35 | 27 (6.6) | 1 (0.6) | 26 (11.0) | 22 (5.6) | 5 (23.8) | |||
| 39 | 4 (1.0) | 0 (0.0) | 4 (1.7) | 4 (1.0) | 0 (0.0) | |||
| 45 | 2 (0.5) | 0 (0.0) | 2 (0.8) | 1 (0.3) | 1 (4.8) | ++++§ | ++++ | |
| 51 | 20 (4.9) | 3 (1.7) | 17 (7.2) | 19 (4.9) | 1 (4.8) | |||
| 52 | 32 (7.8) | 2 (1.1) | 30 (12.7) | 28 (7.2) | 4 (19.0) | ++++ | ||
| 56 | 4 (1.0) | 1 (0.6) | 3 (1.3) | 4 (1.0) | 0 (0.0) | |||
| 58 | 24 (5.8) | 1 (0.6) | 23 (9.7) | 21 (5.4) | 3 (14.3) | ++++ | ||
| 59 | 13 (3.2) | 2 (1.1) | 11 (4.7) | 13 (3.3) | 0 (0.0) | |||
| Total number of infections‡ | 171 (48.7) | 12 (48.0) | 159 (48.8) | 151 (49.5) | 20 (43.5) | |||
| Subjects with probably or possibly hr-HPV infections, n (%) | 54 (13.1) | 5 (2.8) | 49 (20.8) | 50 (12.8) | 4 (19.0) | |||
| 26 | 1 (0.2) | 0 (0.0) | 1 (0.4) | 1 (0.3) | 0 (0.0) | |||
| 53 | 24 (5.8) | 1 (0.6) | 23 (9.7) | 22 (5.6) | 2 (9.5) | |||
| 66 | 10 (2.4) | 1 (0.6) | 9 (3.8) | 9 (2.3) | 1 (4.8) | |||
| 68 | 3 (0.7) | 0 (0.0) | 3 (1.3) | 3 (0.8) | 0 (0.0) | |||
| 70 | 12 (2.9) | 2 (1.1) | 10 (4.2) | 11 (2.8) | 1 (4.8) | |||
| 73 | 2 (0.5) | 0 (0.0) | 2 (0.8) | 2 (0.5) | 0 (0.0) | |||
| 82 | 6 (1.5) | 1 (0.6) | 5 (2.1) | 6 (1.5) | 0 (0.0) | |||
| 85 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||
| Total number of infections‡ | 58 (16.5) | 5 (20.0) | 53 (16.3) | 54 (17.7) | 4 (8.7) | |||
| Subjects with lr-HPV infections, n (%) | 89 (21.6) | 7 (4.0) | 82 (34.7) | 79 (20.2) | 12 (57.1) | |||
| 6 | 24 (5.8) | 2 (1.1) | 22 (9.3) | 21 (5.4) | 3 (14.3) | ++++ | ++++ | |
| 11 | 8 (1.9) | 2 (1.1) | 6 (2.5) | 6 (1.5) | 2 (9.5) | ++++ | ++++ | |
| 40 | 6 (1.5) | 0 (0.0) | 6 (2.5) | 5 (1.3) | 1 (4.8) | |||
| 42 | 11 (2.7) | 0 (0.0) | 11 (4.7) | 10 (2.6) | 1 (4.8) | |||
| 43 | 1 (0.2) | 1 (0.6) | 0 (0.0) | 1 (0.3) | 0 (0.0) | |||
| 44 | 3 (0.7) | 0 (0.0) | 3 (1.3) | 3 (0.8) | 0 (0.0) | |||
| 54 | 7 (1.7) | 0 (0.0) | 7 (3.0) | 4 (1.0) | 3 (14.3) | |||
| 61 | 13 (3.2) | 0 (0.0) | 13 (5.5) | 11 (2.8) | 2 (9.5) | |||
| 62 | 14 (3.4) | 1 (0.6) | 13 (5.5) | 11 (2.8) | 3 (14.3) | |||
| 71 | 2 (0.5) | 0 (0.0) | 2 (0.8) | 2 (0.5) | 0 (0.0) | |||
| 72 | 2 (0.5) | 0 (0.0) | 2 (0.8) | 1 (0.3) | 1 (4.8) | |||
| 81 | 10 (2.4) | 0 (0.0) | 10 (4.2) | 7 (1.8) | 3 (14.3) | |||
| 83 | 8 (1.9) | 1 (0.6) | 7 (3.0) | 7 (1.8) | 1 (4.8) | |||
| 84 | 12 (2.9) | 1 (0.6) | 11 (4.7) | 10 (2.6) | 2 (9.5) | |||
| 89 | 1 (0.2) | 0 (0.0) | 1 (0.4) | 1 (0.3) | 0 (0.0) | |||
| Total number of infections‡ | 122 (34.8) | 8 (32.0) | 114 (35.0) | 100 (32.8) | 22 (47.8) | |||
++++ Genotype covered by the vaccine.
++++§ Genotype highly covered through vaccine crossprotection.
++++ρ Genotype moderately covered through vaccine crossprotection.
*The denominator is total subjects.
†The denominator is total subjects.
‡The denominator is number of HPV infections.
HPV, human papillomavirus; lr-HPV, low-risk HPV; hr-HPV, high-risk HPV.